Clinical trials: Leukemia
Acute Myeloid Leukemia, Maintenance Treatment
The Maintenance Treatment of "ITIVA" in AML Patients
We apply for this clinical study to evaluate the efficacy of "combined recombinant human interference'- α- 1b, interleukin-2, and thalidomide" regimen in obtaining MRD positive AML patients in CR,as well as the efficacy of the…
- Conditions
- Acute Myeloid Leukemia, Maintenance Treatment, Minor Residue Disease, Interferon-α-1b
- Trial name
- NCT06256627
- Testing
- recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Henan Cancer Hospital
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005641
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia
Erwinase Study in Patients With Acute Lymphoblastic Leukemia
The goal of this clinical research study is to allow doctors to use Erwinia L-Asparaginase (Erwinase®) as a replacement for patients who are allergic to E.coli L-asparaginase or Pegylated E.coli L-asparaginase as part of the…
- Trial name
- NCT00506597
- Testing
- Erwinase
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia
Feasibility of Risk-Adapted Therapy in Young Adult Acute Lymphoblastic Leukemia: a Multicenter Trial
Several prognostic predictors, including baseline ALL features and response to initial therapy, have been described in adult ALL raising the issue of whether these predictors might be redundant and which must be considered for…
- Trial name
- GRAALL2003 (NCT00222027)
- Testing
- Collection of treatment-stratefying prognostic factors
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Toulouse
Tumor Lysis Syndrome
Elitek (Rasburicase) Immuno-Monitoring Study
Primary Objective: To determine the incidence, titer and type of anti-rasburicase antibodies in the context of hypersensitivity reaction(s) or the loss of uricolytic activity occurring in patients with relapsed leukemia/lymphoma…
- Trial name
- NCT01097369
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Sanofi
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Asciminib Roll-over Study
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
- Trial name
- NCT04877522
- Testing
- Asciminib single agent, Imatinib, Nilotinib
- Where
- 85 sites in United States, Argentina and 27 more
- Volunteers
- 347 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Lymphoma
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00002718
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia (Both ALL and AML), Brain Tumors
Efficacy of a Smart Holistic Health Care Platform Intervention on Cancer Children and Parents' Bio-Psycho-Social and Spiritual Health
This multicenter randomized controlled trial aims to develop and evaluate two Smart Holistic Health Care Platforms (SHHCPs) for families of children with cancer in Taiwan: the Parent Smart Holistic Health Care Platform (P-SHHCP)…
- Trial name
- NCT07805096
- Testing
- Parent Smart Holistic Health Care Platform (P-SHHCP), Child Smart Holistic Health Care Platform (C-SHHCP)
- Where
- Taiwan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Defense Medical University, Taiwan
Acute Lymphoblastic Leukemia, B-All
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Background: Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy involves taking immune cells (T cells) from a person and modifying them to better target cancer cells.
- Trial name
- NCT07328503
- Testing
- CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
B-cell Acute Lymphoblastic Leukemia
Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with B-cell Acute Lymphoblastic Leukemia with an Option of Extended Use of Forodesine Hydrochloride
- Trial name
- NCT00289562
- Testing
- forodesine hydrochloride (BCX-1777)
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- BioCryst Pharmaceuticals
Leukemia, Acute Myeloid Leukemia
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
The goal of this clinical research study is to learn if giving busulfan and fludarabine before a stem cell transplant can help control the disease better than the standard method in patients with leukemia, lymphoma, multiple…
- Conditions
- Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia
- Trial name
- NCT01572662
- Testing
- Fludarabine monophosphate, Busulfan, Stem Cell Infusion
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
AHN-12 Biodistribution in Advanced Leukemia
This study is a single institution phase I study for the treatment of patients with relapsed or refractory leukemia aged 12 years and older using 90Y-AHN-12.
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT01207076
- Testing
- 90Y-AHN-12
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Lymphoblastic Leukemia
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Both of bortezomib and vorinostat have identified Phase II doses for pediatric and adult patients of which no grade 4 dose limiting toxicities have been observed in prior studies.
- Trial name
- NCT01312818
- Testing
- Bortezomib, Vorinostat, Dexamethasone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lymphoma
Bleomycin in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bleomycin in treating patients with non-Hodgkin's…
- Trial name
- NCT00003110
- Testing
- bleomycin sulfate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
This is a single center 2-phase study to assess effects of using text messages on adherence to oral chemotherapy for patients with acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma.
- Trial name
- NCT06446661
- Testing
- High Intensity, No Text Messagings, Low Intensity Text Messaging
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Chicago
Myelodysplastic Syndromes, Acute Leukemia
Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia
RATIONALE: Giving chemotherapy and total marrow and lymphoid irradiation before allogeneic hematopoietic cell transplant helps stop the growth of leukemia cells.
- Trial name
- NCT03408210
- Testing
- total body irradiation, total marrow and lymphoid irradiation
- Where
- China
- Volunteers
- 191 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Acute Myeloid Leukemia
Universal CAR-T Cells Targeting AML
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T-cell products targeting CLL-1, CD33, CD38 and CD123 in patients with relapsed and refractory AML.
- Trial name
- NCT05995041
- Testing
- CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia in Relapse
Yoga Fatigue Study
Fatigue is a major problem in children, adolescents and adults receiving intensive chemotherapy for cancer and in patients undergoing hematopoietic stem cell transplantation (HSCT).
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia in Relapse, Burkitt's Lymphoma Stage III, Burkitt's Lymphoma Stage IV
- Trial name
- NCT02134782
- Testing
- Individualized Yoga Intervention Group, iPad Activity Control Group
- Where
- 3 sites in United States, Canada
- Volunteers
- 125 people
- Sponsor
- The Hospital for Sick Children
Acute Lymphoblastic Leukemia
Clinical Significance of Occult Central Nervous System Disease In Adult Acute Lymphoblastic Leukemia
Central nervous system involvement at diagnosis remains an obstacle to a long-term cure of patients affected by acute lymphoblastic leukemia.
- Trial name
- NCT03803670
- Testing
- evaluation of cerebrospinal fluid of ALL
- Volunteers
- 241 people
- Sponsor
- University of Rome Tor Vergata
Pediatric ALL, Critical Illness
Singapore's Health Outcomes After Critical Illness in Kids
What is the problem? Every year about 2.5 million children are affected by critical illness and require admission to the pediatric intensive care unit (PICU).
- Conditions
- Pediatric ALL, Critical Illness, Post Intensive Care Unit Syndrome
- Trial name
- SHACK (NCT04637113)
- Testing
- This is a non-interventional study
- Where
- Singapore
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- KK Women's and Children's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.